US SB3094 | 2015-2016 | 114th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on June 23 2016 - 25% progression, died in committee
Action: 2016-06-23 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on June 23 2016 - 25% progression, died in committee
Action: 2016-06-23 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
PRICED Act Price Relief, Innovation, and Competition for Essential Drugs Act This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period. This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
Title
PRICED Act Price Relief, Innovation, and Competition for Essential Drugs Act
Sponsors
Sen. Sherrod Brown [D-OH] | Sen. John McCain [R-AZ] |
History
Date | Chamber | Action |
---|---|---|
2016-06-23 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB5573 (Same As) 2016-06-23 - Referred to the House Committee on Energy and Commerce.
Subjects
Drug safety, medical device, and laboratory regulation
Health
Licensing and registrations
Marketing and advertising
Health
Licensing and registrations
Marketing and advertising
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/114th-congress/senate-bill/3094/all-info |
Text | https://www.congress.gov/114/bills/s3094/BILLS-114s3094is.pdf |